Welcome to our dedicated page for Processa Pharmaceuticals SEC filings (Ticker: PCSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Processa Pharmaceuticals, Inc. (PCSA) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage pharmaceutical company listed on the Nasdaq Capital Market, Processa uses filings such as Forms 8-K, proxy statements, and registration statements to report material events related to its capital structure, shareholder votes, financing transactions, and listing status.
Recent Form 8-K filings detail key corporate actions, including a 1-for-25 reverse stock split of issued and outstanding common shares implemented through a Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation. The filings explain that the reverse split became effective in December 2025, that the par value of the common stock was unchanged, and that the stock continued to trade on Nasdaq under the PCSA symbol with a new CUSIP number. Earlier 8-K and 8-K/A filings describe shareholder approval of amendments to increase authorized common shares from 100,000,000 to 1,000,000,000 and to authorize a reverse stock split within a specified ratio range.
Filings also address Nasdaq listing compliance. In an 8-K dated August 8, 2025, Processa reported receiving a second 180-day grace period from Nasdaq to regain compliance with the $1.00 minimum bid price requirement, and noted that it might implement a reverse stock split to cure the deficiency. Additional 8-Ks and the definitive proxy statement (DEF 14A) provide details on special meetings of stockholders, quorum issues, adjournments, and final voting results on proposals related to authorized share increases, the reverse stock split, and amendments to the company’s omnibus incentive plan.
Capital-raising activities are also documented in SEC filings. For example, an 8-K filed in June 2025 describes the pricing of a public offering of common stock (and pre-funded warrants in lieu thereof) with associated common warrants, stating that net proceeds are intended to support the Phase 2 NGC-Cap trial and general corporate purposes. Another 8-K filed in August 2025 outlines a private placement securities purchase agreement with an accredited investor, including gross proceeds, use of proceeds for general corporate purposes, and placement agent compensation.
On Stock Titan, these filings are supplemented by AI-powered summaries that highlight the most important points from each document, such as changes to authorized shares, reverse stock split terms, Nasdaq notices, and financing structures. Users can quickly see how each filing affects Processa’s capital structure, listing status, and governance, while still having the option to review the full text of the original SEC documents. As additional quarterly and annual reports (Forms 10-Q and 10-K), proxy statements, and Form 4 insider transaction reports become available on EDGAR, they are incorporated into this page with real-time updates and plain-language explanations.
Processa Pharmaceuticals, Inc. Chief Executive Officer George K. Ng bought additional company stock. On March 31, 2026, he made an open-market purchase of 2,136 shares of Processa common stock at $2.535 per share.
Following this transaction, Ng directly holds 3,649 common shares. He also has indirect ownership of 3,488 shares through an account labeled "George Ng IRRA FOB George Ng" and 800 shares through the "Ng Cha Family Trust," giving him a larger combined economic stake in PCSA.
Processa Pharmaceuticals, Inc. Chief Business & Strategy Officer Patrick Lin made an open-market purchase of 1,603 shares of common stock at $2.535 per share. Following this transaction, he directly holds 3,356 shares. In addition, 1,740 shares are held indirectly through the Lin Family Trust dated February 4, 2024.
Processa Pharmaceuticals Chief Administrative Officer Wendy Guy bought shares in the company. On the open market, she purchased 1,854 shares of common stock at $2.535 per share, increasing her direct holdings to 3,110 shares. She also has indirect ownership of 333 shares held by CorLyst, LLC.
Processa Pharmaceuticals’ Chief Development Officer, Bigora Sian, purchased common stock in the open market. On March 31, 2026, Sian bought 2,107 shares of Processa Pharmaceuticals common stock at $2.535 per share, increasing direct ownership to 3,711 shares. The filing also reports indirect ownership of 267 shares held through CorLyst, LLC.
Processa Pharmaceuticals director Baluch Khoso bought shares of the company in the open market. On this transaction date, he purchased 2,269 shares of Common Stock at an average price of $2.535 per share in an open-market purchase. Following this trade, he directly owns 2,325 Processa Pharmaceuticals common shares.
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on Next Generation Cancer (NGC) therapies that modify how existing chemotherapy drugs are metabolized or distributed to improve safety and efficacy. Its lead candidate, NGC-Cap (PCS6422 plus capecitabine), has completed a Phase 1B trial in refractory gastrointestinal cancers and is now in a global Phase 2 trial in advanced or metastatic breast cancer, temporarily paused after dosing 20 patients pending an interim analysis expected in the first half of 2026.
The company is also advancing NGC-Iri (PCS11T), a next-generation irinotecan, and is seeking to monetize two non-oncology assets, PCS12852 for gastroparesis and PCS499 for kidney disease. Processa emphasizes a proprietary Regulatory Science Approach aligned with FDA’s Project Optimus to select optimal dosing regimens and improve approval odds. As of March 13, 2026, it reported 2,660,039 common shares outstanding and held $1.4 million in Chiliz (CHZ) tokens with an unrealized gain of about $77,000 as part of an emerging digital asset treasury strategy.
The Chiliz Group Ltd, formerly HX Entertainment, reports a 13.0% beneficial ownership stake in Processa Pharmaceuticals’ common stock. It holds 305,644 shares with sole voting and dispositive power. This reflects its role as a significant strategic investor in the company.
The Chiliz Group’s total investment of approximately $1,443,784 includes an August 2025 purchase (later adjusted by a 1-for-25 reverse split) and a new February 13, 2026 purchase of 86,956 shares at $2.30 per share for $200,000, funded from internal working capital.
Processa Pharmaceuticals, Inc. reported that its Binding Term Sheet with Intact Therapeutics, signed on June 17, 2025, relating to PCS12852, expired on February 12, 2026. Because a definitive license agreement was never executed, the related proposed amendment to the existing License Agreement with Yuhan Corporation was also not entered into.
With the expiration of the Term Sheet, neither Processa nor Intact Therapeutics has any further obligations under that agreement, effectively ending the previously contemplated PCS12852 licensing arrangement under these terms.
Processa Pharmaceuticals received an amended Schedule 13G showing that investors Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC collectively reported beneficial ownership of 200,000 shares of common stock issuable upon exercise of a warrant held by Intracoastal.
As of December 31, 2025, these warrant shares represented approximately 8.1% of Processa’s common stock, based on 2,265,768 shares outstanding as of December 12, 2025 plus the 200,000 warrant shares. The filers report shared voting and dispositive power over all 200,000 shares and certify the holding is not for the purpose of changing or influencing control.
Processa Pharmaceuticals director and officer David Young, President of Research & Development, reported the vesting and distribution of restricted stock units into common stock on January 1, 2026. A total of 49 restricted stock units were converted at an exercise price of $0, resulting in 49 common shares acquired.
Following this transaction, Young holds 8,752 Processa common shares directly. He also has indirect beneficial ownership of common stock, including 1,242 shares through the Young-Plaisance Revocable Trust, 432 shares through family entities, and 742 shares through CorLyst, LLC. The filing describes the event as a distribution of vested restricted shares.